Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: Effects of preoperative chemotherapy

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Koda, Mariusz ^a   Kanczuga Koda, Luiza ^a   Sulkowska, Mariola ^a   Surmacz, Eva ^b   Sulkowski, Stanislaw ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUOROURACIL; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; LEPTIN; LEPTIN RECEPTOR; METHOTREXATE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; HIF1A PROTEIN, HUMAN; LEPTIN RECEPTOR, HUMAN; SLC2A1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREOPERATIVE PERIOD; PRIMARY TUMOR; PROTEIN EXPRESSION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CANCER STAGING; CELL HYPOXIA; CHEMISTRY; METASTASIS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL HYPOXIA; CHEMOTHERAPY, ADJUVANT; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LEPTIN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, LEPTIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77953672808     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-320     Document Type: Article

References (56)

1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26:225-239. 10.1007/s10555-007-9055-1, 17440684.
2. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007, 67:563-572. 10.1158/0008-5472.CAN-06-2701, 17234764.
3. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, Turley H, Harris AL, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer 2005, 93:1128-1136. 10.1038/sj.bjc.6602828, 2361504, 16251878.
4. Vaupel P, Mayer A, Briest S, Höckel M. Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv Exp Med Biol 2005, 566:333-342. full_text, 16594170.
5. Gardner LB, Corn PG. Hypoxic regulation of mRNA expression. Cell Cycle 2008, 7:1916-1924.
6. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995, 270:1230-1237. 10.1074/jbc.270.3.1230, 7836384.
7. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995, 92:5510-5514. 10.1073/pnas.92.12.5510, 41725, 7539918.
8. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000, 14:391-396. 316386, 10691731.
9. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732. 10.1038/nrc1187, 13130303.
10. Marignol L, Lawler M, Coffey M, Hollywood D. Achieving hypoxia-inducible gene expression in tumors. Cancer Biol Ther 2005, 4:359-364.
11. Nangaku M, Eckardt KU. Hypoxia and the HIF system in kidney disease. J Mol Med 2007, 85:1325-1330. 10.1007/s00109-007-0278-y, 18026918.
12. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001, 93:309-314. 10.1093/jnci/93.4.309, 11181778.
13. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB. Hypoxia-inducible factor-1α expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006, 12:4562-4568. 10.1158/1078-0432.CCR-05-2690, 16899602.
14. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835.
15. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, Worrall L, Gillies RJ. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 2007, 97:646-653. 10.1038/sj.bjc.6603922, 2360372, 17687336.
16. Wincewicz A, Sulkowska M, Koda M, Kanczuga-Koda L, Witkowska E, Sulkowski S. Significant coexpression of GLUT-1, Bcl-xL, and Bax in colorectal cancer. Ann N Y Acad Sci 2007, 1095:53-61. 10.1196/annals.1397.007, 17404017.
17. Sulkowska M, Wincewicz A, Sulkowski S, Koda M, Kanczuga-Koda L. Relations of TGF-β1 with HIF-1α, GLUT-1 and longer survival of colorectal cancer patients. Pathology 2009, 41:254-260. 10.1080/00313020802579318, 19142800.
18. Cooper R, Sarioǧlu S, Sökmen S, Füzün M, Küpelioǧlu A, Valentine H, Görken IB, Airley R, West C. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. Br J Cancer 2003, 89:870-876. 10.1038/sj.bjc.6601202, 2394489, 12942120.
19. Williams KJ, Telfer BA, Airley RE, Peters HP, Sheridan MR, van der Kogel AJ, Harris AL, Stratford IJ. A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene 2002, 21:282-290. 10.1038/sj.onc.1205047, 11803471.
20. Hayashi M, Sakata M, Takeda T, Yamamoto T, Okamoto Y, Sawada K, Kimura A, Minekawa R, Tahara M, Tasaka K, Murata Y. Induction of glucose transporter 1 expression through hypoxia-inducible factor 1α under hypoxic conditions in trophoblast-derived cells. J Endocrinol 2004, 183:145-154. 10.1677/joe.1.05599, 15525582.
21. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJ. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res 1998, 4:115-120. 10.1007/BF02904704, 9654596.
22. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A, Burstein DE. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998, 83:34-40. 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E, 9655290.
23. Rastogi S, Banerjee S, Chellappan S, Simon GR. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 2007, 257:244-251. 10.1016/j.canlet.2007.07.021, 17910902.
24. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006, 207:12-22. 10.1002/jcp.20472, 16110483.
25. Surmacz E. Obesity hormone leptin: a new target in breast cancer?. Breast Cancer Res 2007, 9:301. 1851379, 17274833.
26. Riolfi M, Ferla R, Del Valle L, Piña-Oviedo S, Scolaro L, Micciolo R, Guidi M, Terrasi M, Cetto GL, Surmacz E. Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol
27. Sulkowska M, Golaszewska J, Wincewicz A, Koda M, Baltaziak M, Sulkowski S. Leptin - from regulation of fat metabolism to stimulation of breast cancer growth. Pathol Oncol Res 2006, 12:69-72. 10.1007/BF02893446, 16799705.
28. Koda M, Sulkowska M, Wincewicz A, Kanczuga-Koda L, Musiatowicz B, Szymanska M, Sulkowski S. Expression of leptin, leptin receptor, and hypoxia-inducible factor 1α in human endometrial cancer. Ann N Y Acad Sci 2007, 1095:90-98. 10.1196/annals.1397.013, 17404022.
29. Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E, Sulkowski S. Overexpression of the obesity hormone leptin in human colorectal cancer. J Clin Pathol 2007, 60:902-906. 10.1136/jcp.2006.041004, 17660334.
30. Koda M, Sulkowska M, Kanczuga-Koda L, Cascio S, Colucci G, Russo A, Surmacz E, Sulkowski S. Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1α in human colorectal cancer. Ann Oncol 2007, 18(Suppl 6):116-119.
31. Koda M, Sulkowska M, Kanczuga-Koda L, Jarzabek K, Sulkowski S. Expression of leptin and its receptor in female breast cancer in relation with selected apoptotic markers. Folia Histochem Cytobiol 2007, 45(Suppl 1):187-191.
32. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007, 14:189-206. 10.1677/ERC-06-0068, 17639037.
33. Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, Auriemma A, Molino A, Parolin V, Di Stefano B, Bonetti F, Giordano A, Cetto GL, Surmacz E. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008, 8:305. 10.1186/1471-2407-8-305, 2588622, 18945363.
34. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S, Surmacz E. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 2006, 12:1447-1453. 10.1158/1078-0432.CCR-05-1913, 16533767.
35. Grosfeld A, Andre J, Hauguel-De Mouzon S, Berra E, Pouyssegur J, Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 2002, 277:42953-42957. 10.1074/jbc.M206775200, 12215445.
36. Bartella V, Cascio S, Fiorio E, Auriemma A, Russo A, Surmacz E. Insulin-dependent leptin expression in breast cancer cells. Cancer Res 2008, 68:4919-4927. 10.1158/0008-5472.CAN-08-0642, 18559540.
37. Cascio S, Bartella V, Auriemma A, Johannes GJ, Russo A, Giordano A, Surmacz E. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1α. Oncogene 2008, 27:540-547. 10.1038/sj.onc.1210660, 17653093.
38. Terrasi M, Fiorio E, Mercanti A, Koda M, Moncada CA, Sulkowski S, Merali S, Russo A, Surmacz E. Functional analysis of the -2548G/A leptin gene polymorphism in breast cancer cells. Int J Cancer 2009, 125:1038-1044. 10.1002/ijc.24372, 19408304.
39. Tavassoli FA. Tumours of the breast. Pathology and genetics of tumours of the breast and female genital organs 2003, 9-112. Lyon: IARC Press, Tavassoli FA, Devilee P.
40. Koda M, Sulkowski S, Kanczuga-Koda L, Surmacz E, Sulkowska M. Expression of ERα, ERβ and Ki-67 in primary tumors and lymph node metastases in breast cancer. Oncol Rep 2004, 11:753-759.
41. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006, 59:15-26. 10.1016/j.critrevonc.2005.12.003, 16716598.
42. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97:1573-1581. 10.1002/cncr.11246, 12627523.
43. Li J, Shi M, Cao Y, Yuan W, Pang T, Li B, Sun Z, Chen L, Zhao RC. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun 2006, 342:1341-1351. 10.1016/j.bbrc.2006.02.094, 16516853.
44. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, Eck MJ. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 2002, 99:5367-5372. 10.1073/pnas.082117899, 122775, 11959990.
45. Zhang C, Li K, Wei L, Li Z, Yu P, Teng L, Wu K, Zhu J. p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma. J Clin Pathol 2007, 60:1249-1253. 10.1136/jcp.2006.044099, 17965222.
46. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001, 276:9519-9525. 10.1074/jbc.M010144200, 11120745.
47. Vleugel MM, Shvarts D, van der Wall E, van Diest PJ. p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. Hum Pathol 2006, 37:1085-1092. 10.1016/j.humpath.2006.03.015, 16867872.
48. Cooper C, Liu GY, Niu YL, Santos S, Murphy LC, Watson PH. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res 2004, 10:8720-8727. 10.1158/1078-0432.CCR-04-1235, 15623657.
49. Kurebayashi J, Otsuki T, Moriya T, Sonoo H. Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 2001, 92:1093-1101.
50. Cho J, Kim D, Lee S, Lee Y. Cobalt chloride-induced estrogen receptor alpha down-regulation involves hypoxia-inducible factor-1α in MCF-7 human breast cancer cells. Mol Endocrinol 2005, 19:1191-1199. 10.1210/me.2004-0162, 15695373.
51. Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, Lee JH, Lee SG, Park YK. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 2002, 93:1123-1128.
52. Rastogi S, Banerjee S, Chellappan S, Simon GR. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 2007, 257:244-251. 10.1016/j.canlet.2007.07.021, 17910902.
53. Coradini D, Pellizzaro C, Speranza A, Daidone MG. Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens. Cell Mol Life Sci 2004, 61:76-82. 10.1007/s00018-003-3324-0, 14704855.
54. Koda M, Lenczewski A, Sulkowska M, Kanczuga-Koda L, Wincewicz A, Tomaszewski J, Sulkowski S. The effect of chemotherapy on status of estrogen receptors in primary tumors and lymph node metastases of human ductal breast cancer. Oncol Rep 2007, 17:385-391.
55. Koda M, Sulkowska M, Kanczuga-Koda L, Tomaszewski J, Kucharczuk W, Lesniewicz T, Cymek S, Sulkowski S. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer. Oncol Rep 2007, 18:113-119.
56. Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg 1996, 62:162-165.